Deep brain stimulation (DBS) has become a routine treatment option for improving function and quality of life in patients with various movement disorders and for whom medical treatment has proved insufficient. The short-term efficacy of DBS of the subthalamic nucleus (STN) or globus pallidus interna (GPi) among patients with Parkinson disease (PD) has been demonstrated repeatedly. However, far fewer data on long-term outcomes of the surgery have been collected.
Deep brain stimulation (DBS) has become a routine treatment option for improving function and quality of life in patients with various movement disorders and for whom medical treatment has proved insufficient. The short-term efficacy of DBS of the subthalamic nucleus (STN) or globus pallidus interna (GPi) among patients with Parkinson disease (PD) has been demonstrated repeatedly. However, far fewer data on long-term outcomes of the surgery have been collected.
Twenty-five years after the first report of unilateral DBS of the STN 1 , studies of long-term outcomes of DBS are emerging, thereby providing a body of evidence on its effectiveness and its safety. This evidence is important, as it should be considered when the timing and appropriateness of surgery are discussed with a patient who is likely to need long-term therapy.
Here, we critically review the published evidence that relates to long-term outcomes of DBS for PD and consider the clinical implications of this evidence. We focus on studies in which the follow-up period was at least 5 years because the evidence suggests that this point is important for disease progression and because the number of articles with longer follow-up periods is limited.
Development of DBS
The modern era of DBS began in the 1980s when Benabid et al. published studies in which patients with PD who had drug-resistant tremor were successfully treated with chronic, high-frequency stimulation of the ventro-intermediate nucleus of the thalamus 2, 3 . Before this work, stimulation had been performed mainly during surgical procedures, such as thalamotomy, to test the accuracy of electrode placement in the brain 4 . The advent of implantable pulse generators capable of delivering long-term high-frequency stimulation enabled the approach used by Benabid et al., and use of thalamic DBS subsequently started to replace thalamotomy, with the advantages that the stimulation dose and location could be titrated to maximize the tremor response but minimize stimulation-provoked adverse effects. In addition, DBS made bilateral procedures safer than bilateral thalamotomy.
STN DBS was subsequently developed, and the first series of three patients with bilateral STN was published 5 . This work has since been supported by an increasing number of open-label series and randomized trials [6] [7] [8] [9] , all of which have demonstrated an advantage of STN DBS over conventional medical treatment during short-term follow-up periods.
Long-term outcomes of deep brain stimulation in Parkinson disease
Work conducted in parallel has also shown that chronic DBS of the GPi can lead to benefits in motor control in PD. Overall, very little detectable difference in quality-of-life improvements has been seen between the two procedures [10] [11] [12] [13] , although most investigators conclude that STN DBS has greater beneficial effects than GPi DBS on symptoms in off periods in PD (Box 1), thereby enabling reductions in medication for these symptoms, whereas GPi DBS reduces 3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia to a greater extent.
Assessment of long-term outcomes
Assessment of the long-term effects of DBS is heavily dependent on the outcome measure chosen. In most studies, the reported outcomes are the effects of DBS on the severity of PD (assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) part II (activities of daily living), part III (motor subsection) and part IV (complications of therapy) and/or one of several available dyskinesia rating scales) in off periods and on periods. These measures provide a clear cross-sectional snapshot of the therapeutic efficacy but do not necessarily provide a complete assessment of patients' true daytime function. An alternative approach is to focus on the patient's perspective and measure the overall quality of life by use of the disease-specific PDQ39 (39-item Parkinson's Disease Questionnaire). However, long-term quality-of-life data have been collected in only a limited number of studies.
Adverse outcomes of long-term DBS are also important and must be assessed. Adverse events are mostly assessed by clinical examination and listening to the patient's observations. Adverse effects of the implantation surgery are fortunately rare, and rates of symptomatic haemorrhage and infection are generally low. By contrast, adverse effects of stimulation, such as dysarthric speech, swallowing disturbances, freezing of gait and balance disturbances, are increasingly being recognized and can occur with use of stimulation parameters that are optimal for improving tremor, rigidity and bradykinesia. PD progression undoubtedly continues despite DBS surgery, therefore distinguishing stimulation-induced adverse effects from disease progression can be difficult; the most convincing demonstration that adverse effects are caused by the DBS is resolution of the effects with adjustment of stimulation parameters.
Reported long-term outcomes
We identified 15 studies of STN DBS in which outcome measures included UPDRS part III scores that were recorded preoperatively and after 5 years (to enable analysis of the motor effects of DBS) when patients were in off periods but receiving DBS [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . We identified only two similar studies of GPi DBS (reported in three articles), which we therefore consider separately [29] [30] [31] . Of the 15 STN DBS studies, 5 included patients for whom follow-up was 8-11 years [20] [21] [22] [23] 27 . Detailed bradykinesia, rigidity and tremor subscores of the UPDRS were reported in 11 of these 15 studies 14, 16, 17, 19, [21] [22] [23] [24] [25] [26] . In other studies, long-term outcome measures of STN DBS other than UPDRS part III have been included, and we include these studies in our discussion. Given the paucity of long-term data on GPi DBS, which hinders the inevitable desire to compare the effects of stimulating these two targets, we include a brief discussion of short-term, randomized comparisons.
STN DBS
Across the 15 identified studies of STN DBS, 5-year outcomes for a total of 551 patients are reported out of 923 patients who underwent electrode implantation at baseline (Supplementary Table 1) . Ninety-nine patients died, but the causes were unrelated to DBS in the vast majority of cases. Other patients were lost to follow-up, were followed up in other centres or had become too disabled to come for assessment because of PD progression or other illness, such as stroke. The mean age at surgery was 52.9-61.4 years (depending on the study), the average duration of disease varied from 6.8 years to 16.4 years and most studies included patients with a disease duration >10 years. There was an excess of men included in most studies. The reported long-term outcomes across these studies are discussed below.
Motor function. The most consistently reported outcome measure was the UPDRS part III motor score recorded when patients were in off periods or on periods (Fig. 1) . In all studies, the UPDRS off-period score when stimulation was switched on was significantly lower (indicating an improvement of symptoms) at 1 year and 5 years than at baseline and at longer follow-up time points in the few studies that included these. Nevertheless, scores clearly indicate that the benefits decrease with longer follow-up. UPDRS on-period scores are generally worse than at baseline by the 5-year time point, despite some improvements seen at 1 year. This observation probably reflects the fact that STN DBS is a symptomatic treatment of the off periods and does not improve symptoms during the on period, which reflects the l-DOPA sensitivity of symptoms at this stage of the disease.
In 11 studies, subscores for motor improvements (tremor, rigidity, bradykinesia and axial features) could be calculated 14, 16, 17, [19] [20] [21] [22] [23] [24] [25] [26] (Supplementary Table 2) . These data clearly demonstrate that substantial DBS-induced improvements in rigidity and tremor during off periods are maintained at 5 years and beyond, whereas beneficial effects of DBS on bradykinesia and axial signs seen at 1 year have started to decline by 5 years. By contrast, in the on periods, akinesia and axial signs have generally
Key points
• Subthalamic nucleus (STN) deep brain stimulation (DBS) can provide long-term improvements in motor function for patients with Parkinson disease (PD).
• STN DBS does not prevent the neurodegenerative processes of PD; therefore, quality-of-life scores have usually fallen to preoperative levels by the 5-year time point.
• Deterioration in quality of life often reflects the emergence of 3,4-dihydroxyphenylalanine (l-DoPA)-refractory or stimulation-resistant motor and non-motor features of PD, particularly impairments of gait, balance and speech.
• Distinguishing stimulation-induced adverse effects from disease progression requires experience, a systematic approach to adjusting stimulation parameters and awareness of possible relationships with changes in dopaminergic medication.
• Important factors in long-term outcomes of DBS are patient selection, precision of electrode targeting and experienced stimulation and medication adjustments.
worsened in comparison with baseline by 5 years. In one study that included 18 patients who had received DBS for an extended period, symptoms in the off period were assessed in these patients by a rater who was blinded as to whether STN stimulation was on or off; the results indicated that at a mean of 10 years after DBS surgery, DBS significantly improved UPDRS part III scores, particularly those for tremor, rigidity and limb bradykinesia 21 . In another study with a similar design and that included 29 patients who were receiving STN DBS, substantial improvements over baseline scores for tremor (85% improvement) and rigidity (66% improvement) were seen at 5 years. At the same time point, improvements in bradykinesia were smaller (38% relative to baseline), and gait and balance scores were approaching baseline severity 19 . In a multicentre, double-blinded assessment study of 31 patients, STN DBS was associated with significant improvements in the off period relative to baseline at 5-6 years after implantation 29 .
The effects of STN DBS on axial signs in PD have also been studied in a meta-regression analysis. This study showed that 'postural instability/gait disturbance' (PIGD) in the off period would, on the basis of extrapolation, worsen to the preoperative state after 9 years, whereas the severity of PIGD in the on period would reach preoperative severity after only 2 years 32 . These findings confirm that STN DBS provides symptomatic treatment for the off periods and that the disease continues to progress.
In four studies, patients who were receiving STN DBS were assessed in an off period and after the stimulation had been stopped for a short period 17, 21, 22, 33 . Surprisingly, this approach identified no significant difference in UPDRS part III scores at 5-10 years when compared with off-period scores at baseline. Worsening relative to baseline was expected, but given that the data were collected only a short time after stimulation was stopped, this observation more likely indicates that the full effects of stimulation have not completely 'washed out' rather than a neuroprotective effect of stimulation.
Of further interest is that the response to levodopa decreases over time in patients who are receiving STN DBS. In one study, the percentage improvement in the off-period UPDRS III score after levodopa was 68% at baseline, 60% at 1 year, 45% at 5 years and 37% at 9 years 22 , and similar figures have been found in other studies 18, 34 . However, this effect is probably related to disease progression, as the rate at which the on-period UPDRS part III score declines has been shown to be similar to that of a control group who did not receive DBS 35 .
Other measures have been used to assess long-term outcomes of STN DBS. Use of UPDRS part IV has demonstrated that STN DBS significantly improves dyskinesia [14] [15] [16] 18, 19, [21] [22] [23] 26 and motor fluctuations and that these improvements mostly persist beyond 5 years 15, 16, 18, 19, [21] [22] [23] . In one study, use of diary data also revealed improvements in motor fluctuations and dyskinesia up to 5 years after STN DBS 28 .
In one study of long-term STN DBS outcomes, a non-operated comparator group was included. Individuals in this group were patients who had been assessed as suitable for DBS but subsequently underwent alternative medical interventions for reasons unrelated to their PD 36 . In this long-term comparison, in which the average follow-up period was 6 years, improvements in motor fluctuation, dyskinesia and activities of daily living in the off period were greater among the group who received STN DBS than among the medically treated group. Comparison of three groups of 20 patients who were treated for 5 years with STN DBS, levodopa carbidopa intestinal gel (LCIG) or oral medical therapy showed that DBS and LCIG were superior to oral therapy for reducing the duration of off periods and improving dyskinesia at 5 years 37 . Less deterioration in activities of daily living was observed in the STN DBS and LCIG groups than in the oral medical therapy group. Furthermore, STN DBS was superior to LCIG for improving dyskinesia and was associated with fewer adverse events.
Activities of daily living and quality of life. Long-term improvements in the activities of daily living subscale (UPDRS part II) during off periods have been demonstrated in several studies. Improvements have consistently been seen for up to 5 years 14, 15, 17, 19, 21, 22, 28 , but longer-term results are more variable. For example, in one study, scores were still improved relative to baseline at 10 years 21 but, in another study, complete loss of improvement was seen at 9 years 22 . However, UPDRS part II on-period scores have usually been worse than at baseline even at 5 years, confirming the observations made for other measures 14, 15, 17, 19, 21, 22, 28 . Quality of life has been assessed with the PDQ39 in several studies, which have uniformly shown that the improvements from baseline that are seen at 1 year have been lost by 5 years 23, 25, 28, 38 . Use of the Parkinson's Disease Quality of Life (PDQL) scale in another study has demonstrated that a significant improvement (20%) over baseline was maintained for up to 5 years, although the magnitude of the improvement declined between years 1 and 5 (reF.
19
).
Non-motor symptoms. Although PD is primarily considered to be a movement disorder, several non-motor symptoms can also occur, and the effects of DBS on these symptoms must also be considered. Long-term studies on non-motor symptoms have largely focused on cognition and psychiatric conditions. Separating the effects that PD progression and DBS have on cognition is a major challenge that requires
Box 1 | On and off periods in Parkinson disease
Although medications for Parkinson disease (PD) alleviate symptoms, their benefit can vary in relation to the time of medication and specific symptoms. The times when medications are effectively alleviating parkinsonian symptoms are referred to as on periods, and the times when medications are not helping are referred to as off periods.
once electrodes are implanted for deep brain stimulation, the stimulation is continuous but can be briefly turned off to enable studies of its effects in on periods and off periods.
www.nature.com/nrneurol either a control group or a clear and reproducible difference in cognitive function between stimulation-on and stimulation-off conditions. In one study of 16 patients who received STN DBS for PD, 31% had developed dementia by 6-9 years after DBS implantation surgery compared with 45% of patients in a comparable, non-operated population 39 . In another study, the rate at which dementia developed after STN DBS was estimated at 35.7 per 1,000 person-years of follow-up; this rate is similar to that among non-operated patients with PD at the same stage of disease 40 . Despite these encouraging results, subtle impairments in cognition have been consistently associated with STN DBS. A decline in verbal fluency has been observed in most studies in which this parameter has been quantified 41 . One study has demonstrated that verbal fluency among patients who receive STN DBS is significantly worse at 8 years after initiation of the treatment than among comparable controls with PD who were eligible for surgery but declined 42 . As expected, cognitive decline was seen in both groups over the follow-up, but no cognitive measures other than verbal fluency differed between them even at the 8-year follow-up. Similarly, many studies in which the Mattis Dementia Rating scale, a global measure of cognition, was used to assess patients receiving DBS found that cognitive function is generally unchanged at 1 year after initiation of DBS but gradually declines by 5 years 14, 15, 17, 23 . This decline could be predicted to some extent on the basis of the degree of impairment in executive function at baseline 28 . Studies of the effects of STN DBS on psychiatric features of PD have shown that these symptoms can either reduce or occur for the first time after STN DBS; many investigators in this field believe that these effects are strongly related to the extent and direction of changes in medication 43 . Several studies have shown that depression scores improve with STN DBS, although these improvements tend to wane with longer follow-up 14, 15, 17, 19, 22, 23, 25, 28 . By contrast, apathy and fatigue scores tend to increase with STN DBS and remain increased in the long term 39, 44 . Scores for these features are higher among patients receiving STN DBS than among comparable non-operated patients with PD 39, 44 . As for psychiatric symptoms, changes in impulsive and/or compulsive behaviours in response to STN DBS can vary; case reports and case series have detailed both complete resolution and the first emergence of these behaviours. These effects are also likely to be related to the extent to which medication is reduced 43, 45 . A long-term study has shown that hyperdopaminergic behaviours, such as hypomania, gambling and compulsive shopping, were all reduced after STN DBS in a series of 69 patients with PD over a mean follow-up of 6 years 44 . The long-term effects of STN DBS on other nonmotor symptoms of PD have been studied to a lesser extent. In a cohort of 24 patients with PD, STN DBS improved PD-related pain for up to 8 years 46 . In another series, sleep diaries revealed that patients who received STN DBS had longer periods of night-time sleep at 5 years after implantation than at baseline 28 .
Adverse effects. Various long-term adverse effects of STN DBS have been observed, but, on the basis of our experience, these effects seem to be vastly under-reported in the published literature. Adverse effects were described in detail in only five long-term studies 14, 15, 17, 19, 20 (TaBle 1) .
Acute complications that arise from the initial surgery are rare but can be life-threatening. Similarly, hardware complications, such as lead fractures and device malfunctions, are rare -estimated rates of such events are 1.4% and 0.5%, respectively -but need to be dealt with promptly 47 . However, in our experience, long-term adverse effects that do occur, such as deterioration of speech or balance, eyelid apraxia and weight gain, are often not formally reported, either because their relationship with DBS is not recognized or because clinicians fail to routinely document their presence. In one study of adverse events of DBS in 123 patients with movement disorders, 82 of whom had PD, 5% of patients with PD had severe long-term adverse events, and 23% of the 78 patients who received STN DBS had non-reversible adverse events 48 . The available data indicate that STN DBS has no adverse effects on long-term survival, which is broadly similar to 16, 35 or slightly better than 49, 50 that among comparable non-operated patients with PD. Most deaths among patients receiving STN DBS are unrelated to the DBS surgery. However, careful documentation shows that the percentage of intelligible speech declines with use of STN DBS, from 91.9% of spoken words understandable at baseline to 80.8% at 1 year, 70.2% at 5 years and 63.5% at 8 years 23 ; this rate of decline was higher than the decline observed in a non-operated group. Average weight gain among 47 patients who received STN DBS was 7.2 kg at 4.7 years after surgery; 57.4% of patients were overweight or obese at the last follow-up, compared with 34% before DBS 51 . One particularly serious adverse event is a withdrawal syndrome. Withdrawal of DBS in patients in whom the duration of disease and stimulation has been long can be life-threatening as it can lead to a severe parkinsonian state that medications are not sufficient to control 52 , and it should be managed promptly by restarting effective stimulation.
Medication changes.
In the 15 studies of STN DBS that include long-term data, the mean baseline levodopa equivalent dosage (LED) was 1,106 mg daily (Supplementary Table 3 ) and the mean percentage reduction in dose after DBS surgery was 52% at 1 year (range 39-83%) and 45% at 5 years (range −11% to 63%). Among the few studies with longer follow-up periods, the dose was reduced by a mean of 42% at the end of follow-up (range 21-60%). This reduction in dopaminergic medication is a good indication of how effectively STN DBS improves PD symptoms. The reduction also minimizes the adverse effects of those medications, in particular dyskinesias and hyperdopaminergic behavioural problems.
Responses to electrical parameters. Most patients in long-term studies of STN DBS received monopolar stimulation through a single contact on each electrode, but some received bipolar or double monopolar stimulation (Supplementary Table 3 ). The mean amplitude of stimulation at 1 year was 2.8 V, which increased to 3.15 V by 5 years. This increase is small and probably reflects that adjustments can be made as the disease progresses, although it could also reflect that local changes take place around the electrode, and this effect is indicated in one study in which therapeutic impedance decreased over time 27 . In several studies, adjustment of the frequency of stimulation has improved control of symptoms. In three studies 17, 20, 21 , use of low-frequency (60 Hz) stimulation in long-term follow-up alleviated freezing of gait and/or dysarthric speech in 64.3% of patients 20 . In another study, an increase in stimulation frequency improved tremor in 55.6% of patients 20 .
Prediction of long-term improvement
An understanding of the factors that affect whether STN DBS is likely to provide long-term improvements would be valuable in making decisions about which patients to treat and when. Intuitively, an important factor is the accuracy with which the active stimulating contact is placed within the STN, and this hypothesis has been confirmed in one study in which 5-year outcomes of STN DBS were better if at least one stimulating contact was located in the sensorimotor part of the STN than if none were 23 . In the same study, younger age at disease onset, worse preoperative off-medication UPDRS score and more severe fluctuations in symptoms between on and off periods were all associated with greater long-term improvement 23 . In another study, preoperative scores for gait disturbance in off periods inversely correlated with 10-year motor outcomes of DBS 21 , and this observation was confirmed with 8-year follow-up data in another study 20 . In one study of 110 patients who received STN DBS, the roles of age and disease duration in determining long-term outcomes were examined 24 . Patients aged >65 years had poorer 5-year outcomes than younger patients, particularly with respect to axial scores, and a longer disease duration at the time of DBS surgery was associated with a worse Schwab and England (activities of daily living) score at follow-up. A comparison Studies included: 14, 15, 17, 19, 20 . In all studies, subthalamic nucleus deep brain stimulation was used.
a Death in the follow-up period; in most cases, death was unrelated to surgery.
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of patients who were still independent in activities of daily living (Schwab and England score >70) at 5 years after DBS surgery with patients who were not demonstrated that the independent variables associated with long-term independence were age at surgery and preoperative Mini Mental State Examination (MMSE) and Schwab and England scores in the off period 53 .
GPi DBS
To date, the outcomes of GPi DBS in PD beyond 5 years have been assessed in only two studies 29, 31 . In the first of these studies 31 , 6 patients (from an initial cohort of 11 individuals) experienced improvements in UPDRS part III scores in off periods that were maintained at 3 years (a reduction of 43%), but the only remaining benefit by 5 years was an improvement in rigidity. Four of the original 11 patients who lost an initial benefit from GPi DBS subsequently underwent STN DBS, which renewed their improvement. In patients who continued to receive GPi DBS, beneficial effects on levodopa-induced dyskinesia were maintained up to 5 years.
In contrast to these generally negative findings, in another study of 16 patients, UPDRS part III scores in the off period were reduced by GPi DBS from a mean baseline of 52.2 to a mean of 33.9, even after 5-6 years of the treatment 29 . Furthermore, compared with patients who had undergone STN DBS, fewer patients exhibited cognitive decline, speech difficulties or gait and balance disorders. The patients who were included in this study had not been randomly allocated to receive the different forms of DBS, which limits the extent to which conclusions can be drawn from the comparison.
Given the lack of studies and the contradictory findings, further studies of the long-term outcomes of GPi DBS are clearly needed. Existing data clearly show that GPi DBS has a sustained beneficial effect on levodopa-induced dyskinesia, but the extent to which symptoms of PD in the off period can be improved has been variable.
Comparison of STN DBS and GPi DBS
Two randomized trials have been conducted to directly compare the outcomes of STN DBS and GPi DBS 10, 12 , although the longest follow-up published to date is only 36 months 11, 13 . In one study, motor symptoms in the off period improved to a greater extent among patients who received STN DBS than among those who received GPi DBS 13 , whereas in another study, motor scores in on periods were better with GPi DBS than with STN DBS 11 . No differences in cognition or psychiatric outcomes were found between patients who received STN DBS and those who received GPi DBS at 3 years 54 . Without randomized studies, direct comparisons between GPi DBS and STN DBS are difficult, and the longer-term outcomes of previously performed trials are therefore eagerly awaited 11, 13 . In the meantime, patients continue to be selected for STN DBS or GPi DBS on the basis of experience and prejudices at individual centres.
Limitations
Existing studies of the long-term outcomes of DBS are limited by several factors. The most obvious issue is that the published data are potentially biased owing to missing data as a result of patient deaths from PD, comorbidity, loss to follow-up, follow-up at other centres and disease severity preventing patient visits for assessment.
In most studies to date, the comparison made is between baseline and follow-up severity of PD, which is of limited value for informing patients on long-term outcomes given that PD is a neurodegenerative process. Consequently, comparable non-operated control groups are needed in future studies. One possibility is a head-to-head long-term comparison of DBS with conventional treatment or with another advanced therapy, such as apomorphine or duodopa. However, the choice of the comparator arm challenges the existing ability of a patient to influence the choice of treatment according to their preference and the ability of a clinician to recommend which treatment they suspect a patient will do better with; both abilities would disappear in a randomized comparison of treatments. The data that are currently available come from either randomized studies that are limited to 1 or 2 years of follow-up [6] [7] [8] [9] or nonrandomized, often retrospective studies 36, 37, 55 . These studies generally indicate superiority of DBS over conventional treatment, LCIG and apomorphine, but in the absence of long-term data from a randomized trial, these comparisons should be interpreted with caution.
Another limitation is that interpretation of long-term data is confounded by medication changes. Assessment in the off period is generally performed after an overnight withdrawal of medication and therefore provides only a surrogate measure of the true underlying PD severity. As a result of DBS, major changes are often made to medication, therefore the effect of overnight withdrawal at different time points might not be equivalent. Furthermore, the alleviation of symptoms as a result of medications (in the on period) can reduce after STN DBS, and it is unclear whether this reduction is related to disease progression and the emergence of l-DOPArefractory signs, a reduction in l-DOPA responsiveness due to DBS or use of a lower dose of medication 34 . In one study, the rate of progression in patients receiving DBS was compared with that in a non-operated population and no difference was seen 35 , but this finding will need to be confirmed in a larger sample. Therefore, within these limitations, the existing evidence suggests that STN DBS maintains usual on-period function for only 2-5 years, whereas the treatment maintains off-period improvements for 9-10 years.
Current and future clinical implications
The published evidence consistently supports the idea that 'well-selected' patients (those who are likely to benefit from surgery and are unlikely to experience adverse effects on the basis of their clinical presentation) gain short-term improvements in quality of life as a result of DBS surgery compared with conventional medical treatment. These benefits persist for the first years after electrode implantation, and additional benefits in the core motor aspects of PD (tremor, rigidity and bradykinesia) persist to 8-10 years. This evidence therefore strongly supports the use of DBS in patients with marked disability as a result of these symptoms.
Nevertheless, the evidence also makes clear that DBS does not prevent disease progression or the development of axial problems, such as disturbances of gait, balance and speech or cognitive disability, which become the major determinants of quality of life in the long term. Furthermore, chronic STN DBS can cause adverse effects, such as dysarthric speech and freezing of gait in particular, and these effects must be recognized by centres that provide DBS services because they might be modifiable with adjustment of stimulation parameters 17, 20, 21, 56 , medication changes or electrode repositioning. Some patients will develop irreversible and disabling axial deficits, and the relative contributions of disease progression and stimulation can be impossible to disentangle. The combination of disease progression and chronic DBS has led to increased recognition of a new PD phenotype characterized by patients who are no longer disabled by tremor, rigidity or dyskinesia but who have poor-quality speech, frequent freezing and falls.
Currently, candidates for DBS are considered to be -according to outcomes in clinical series -people with PD who are younger than 70-75 years, have a good motor response to levodopa, have little or no medical or psychiatric comorbidity and have no major abnormalities on preoperative MRI brain scans 57 but who have some degree of disability (usually motor fluctuations or dyskinesia) that is refractory to adjustments of non-invasive therapies. Within these broad criteria, some patients are presumably likely to have better long-term outcomes than others, and identifying the factors that predict who these patients are would be helpful. One study demonstrated that patients over the age of 65 years developed more severe axial signs during the follow-up 24 , an observation that certainly warrants further study. In addition, data from the Parkinson Progression Markers Initiative study published in 2016 indicate that patients who are older at symptom onset have a greater burden of motor and non-motor symptoms even in the absence of DBS 58 , therefore the long-term outcomes of DBS in older patients might be expected to be unfavourable. Furthermore, some series indicate that for patients with the most severe preoperative gait difficulties, the long-term benefits of DBS are limited 20, 21 . Given that the risks of surgery are lower in younger people with less brain atrophy and that the evidence indicates that the benefits of DBS (at least appendicular motor benefits) are more sustained in younger patients, DBS in patients at early stages of disease (with independent functioning and good quality of life) is being considered 8 . However, the 'very-long-term' effects of DBS (including the possibility of reduced l-DOPA responsiveness) are unknown and would be relevant to patients who undergo surgery early in the disease course. The decision to undertake surgery in any individual patient must therefore consider the potential of both acute and chronic adverse effects of DBS as well as specifically addressing the severity of symptoms at baseline and individual patient expectations.
Knowledge of patient heterogeneity is also increasing and could become increasingly relevant in the surgical decision process. For example, the effects of specific genetic risk factors for PD on the long-term outcomes of patients who undergo DBS are the focus of ongoing studies 59 . There are some data to suggest that patients with mutations in GBA1 have more aggressive disease 60, 61 and that, consequently, their disability progresses to a greater extent after DBS than in those with other forms of PD. Whether this effect simply reflects a more aggressive underlying disease process in these individuals or indicates an interaction between genotype and the surgical intervention requires further study, ideally in a randomized study.
Another uncertainty that affects clinical decisions is the precision with which electrodes must be placed to ensure good long-term outcomes. The limited amount of data currently makes it difficult to gauge how strong the relationship is between the accuracy of electrode placement and long-term improvements in quality of life. Furthermore, stimulation-induced adverse effects, which might result from inaccurate placement of electrodes, can limit the beneficial effects from DBS and can become an increasing challenge with long-term follow-up. The development of improved technology, such as directional DBS electrodes and closed-loop or adaptive DBS, alongside improved imaging and targeting platforms might improve consistency of outcomes.
For patients with PD that is in the most advanced stages (with major gait, balance and cognitive impairments), outcomes of DBS at conventional targets are not good. For this reason, there is interest in DBS of other brain regions, such as the pedunculopontine nucleus or the nucleus basalis of Meynert [62] [63] [64] [65] , with the hope that stimulation will enhance neuronal network activity. To date, the short-term outcomes of these approaches have been variable, and long-term follow-up of patients involved in these studies has not been done. Consequently, these approaches should currently be considered as experimental.
Network-targeted DBS is also being tested in other neurodegenerative disorders, such as Alzheimer disease (AD). As in advanced PD, the aim in AD is to enhance the activity of underactive brain networks by targeting either the fornix or the nucleus basalis of Meynert 66, 67 . Early results indicate that the effects are very mild and inconsistent 66, 67 , in contrast to the marked improvements that were seen in the early trials of STN DBS. These results cast some doubt on the future of DBS for dementia, although the challenges associated with increasing neuronal activity might be quite different from those associated with suppression of abnormal neuronal firing patterns.
Conclusions
The current evidence indicates that STN DBS can improve motor function in PD for over 10 years. Nevertheless, many patients enrolled in studies are lost to follow-up, and outcomes are variable between patients. Dyskinesia and motor fluctuations often remain improved, whereas improvements in axial symptoms and quality of life in the first few years tend www.nature.com/nrneurol to decline over time. Age, severity of PD and the position of electrodes are important predictors of long-term improvement. In contrast to STN DBS, GPi DBS mostly improves dyskinesia in the long term.
In the context of these caveats, the discussion of longterm pros and cons and the timing of surgery is, for many individuals, irrelevant because of the urgency of their clinical situation and the lack of alternative options. For an individual who has severe disability despite multiple attempts at controlling symptoms with conventional medication, DBS has the potential to provide long-term symptom relief, and the available data largely support the use of this clinical approach. By contrast, a young patient for whom conventional medication provides excellent control of symptoms should not be led to believe that the evidence for long-term benefits of DBS is yet sufficient to conclude that initiation of DBS at an early stage is the best option.
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